S.C. Terapia S.A., Sun Pharmaceutical Industries Europe B.V.

Poland

All drugs from this manufacturer

  • ERLOTINIB SUN

    The medicine is intended for adult patients with advanced non-small cell lung cancer (provided specific EGFR mutations are present) or in the case of metastatic pancreatic cancer (in which case it is used in combination with gemcitabine).

    Dosage form: tablets, film-coated

    Active substance Dosage
    erlotinib 25 mg

    ATC: L01XE03

  • The medicinal product is used in adult patients with advanced non-small cell lung cancer (provided that specific EGFR mutations are present) and in patients with metastatic pancreatic cancer (in combination with gemcitabine).

    Dosage form: tablets, film-coated

    Active substance Dosage
    erlotinib 100 mg

    ATC: L01XE03

  • The medicine is used in adult patients for the treatment of advanced non-small cell lung cancer (depending on the cancer cell mutations) and for the treatment of metastatic pancreatic cancer (in combination with gemcitabine).

    Dosage form: tablets, film-coated

    Active substance Dosage
    erlotinib 150 mg

    ATC: L01XE03

  • The medicine is used for the short-term treatment of symptoms of gastroesophageal reflux disease in adults, such as heartburn (painful burning in the chest reaching up to the throat) and acid regurgitation.

    Dosage form: tablets, enteric-coated

    Active substance Dosage
    pantoprazole 20 mg

    ATC: A02BC02

  • The medicine is used to treat bleeding from esophageal varices (bleeding from enlarged veins in a part of the digestive tract leading to the stomach).

    Dosage form: solution for injection

    Active substance Dosage
    terlipressin 0.1 mg/ml

    ATC: H01BA04